Ridgeback Biotherapeutics

Executive Summary

Ridgeback Biotherapeutics is a Miami-based private biotech focused on developing therapies for emerging infectious diseases with limited treatment options. The company gained prominence through its collaboration with Merck on molnupiravir (Lagevrio), an oral antiviral for COVID-19, which received emergency use authorization. Ridgeback's late-stage pipeline also includes a treatment for Ebola, though details are sparse. The company operates with a lean model, outsourcing manufacturing and investing early in development. With a single approved product and limited public pipeline, Ridgeback's near-term value hinges on expanding molnupiravir's label (e.g., pediatric use) or advancing its Ebola candidate. The company's commitment to neglected diseases positions it for potential partnerships or acquisition interest, but revenue concentration and pipeline thinness pose risks.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on molnupiravir for pediatric COVID-1970% success
• Q4 2026Phase 2/3 data readout for Ebola antiviral candidate40% success
• TBDPotential partnership or licensing deal for new infectious disease asset50% success